Journal: Frontiers in Oncology
Article Title: YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
doi: 10.3389/fonc.2024.1304374
Figure Lengend Snippet: Infection with XVir-N-31 (XVir) increases both calreticulin (CALR) and CD47 surface expression on pediatric sarcoma cell lines. (A) Analysis of CALR (‘eat-me’) and CD47 surface expression (‘don’t-eat-me’) surface expression of pediatric sarcoma cell lines A673, SKNMC, and U2OS 48 hours post infection (hpi) at indicated multiplicity of infection (MOI) assessed by FACs analysis after dead cell exclusion via DAPI. Y-axis depicts the fold change of expression compared to controls (ctrl) using frequency of parent minus isotype (IT). (B) Analysis MOI/dose-dependency of CD47 surface expression at 48hpi using indicated MOI. Statistical analysis was performed using the unpaired student’s t-test in (A) and one way ANOVA with multiple comparison and Tukey correction in (B) . Plotted is the mean with SD. Each dot represents one biological replicate. Experiments were repeated at least twice to ensure reproducibility. Levels of significance are indicated as asterisks *p<0,0332; **p<0,0021; ***p<0,0002; ****p<0,0001.
Article Snippet: Following FACS-antibodies were used: CD47 anti-human FITC REA 220 (Miltenyi Biotech), CD47 isotype REA control antibody human IgG1 VioBright B515 REA293 (Miltenyi Biotech), Calreticulin mouse anti-human Alexa Fluor 488 MAB38981 (R&D Systems), Alexa Fluor 488 goat anti-mouse IgG A11029 (Thermo Fisher Scientific), CD11c anti-human APC B-ly6 (BD Biosciences) and CD45 anti-human APC REA747 (Miltenyi Biotech), CD86 anti-human VioBlue REA968 (Miltenyi Biotech), CD80 anti-human PE REA661 (DAPI Staining Solution (Miltenyi Biotec).
Techniques: Infection, Expressing, Comparison